DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Syringocystadenoma Papilliferum — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSyringocystadenoma Papilliferum maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for syringocystadenoma papilliferum is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
HRas proto-oncogene, GTPase (HRAS) — HRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8ELT · 1.66 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Syringocystadenoma papilliferum is a benign adnexal skin tumour that usually appears at birth or during puberty, most often as a solitary lesion on the head and neck. A 2013 case report describes a scalp lesion in an adult male that was clinically mistaken for keratoacanthoma before histological examination confirmed the diagnosis. A 2014 report presents an unusual case of multiple verrucous lesions located on the right flank, an uncommon site outside the head and neck region. No drug treatment is described in any of these reports.
The malignant counterpart, syringocystadenocarcinoma papilliferum, is a rare sweat gland carcinoma. A 2004 report describes a 60-year-old man who had two verrucous plaques on his right auricle since childhood; these became ulcerated, painful, and pruritic over one year. Histopathology confirmed syringocystadenocarcinoma papilliferum. He was treated with Mohs micrographic surgery followed by reconstruction of the right auricle. There were no signs of recurrence or metastasis six years after the operation.
No systemic therapy, topical agent, or repurposed drug is mentioned in any of these abstracts. The only reported successful intervention for the malignant form is surgical excision with margin control. For the benign form, diagnosis is histological and no treatment outcome data are provided.
What is missing are any controlled trials, any drug-based interventions, any data on metastatic or inoperable cases, and any patient stratification beyond single case reports. There is no evidence to support drug repurposing for either syringocystadenoma papilliferum or syringocystadenocarcinoma papilliferum.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatologic Surgery · 2004 · 48 citations
Syringocystadenocarcinoma Papilliferum: Successfully Treated With Mohs Micrographic Surgery
AbstractBACKGROUND: Syringocystadenocarcinoma papilliferum, a rare sweat gland carcinoma, is the malignant counterpart of syringocystadenoma papilliferum. OBJECTIVE: To demonstrate a rare case of syringocystadenocarcinoma papilliferum successfully treated with Mohs micrographic surgery. METHODS: A 60-year-old male presented with two verrucous plaques on his right auricle since childhood. These two plaques became ulcerated, more painful, and pruritic in 1 year. Histopathologic examination revealed syringocystadenocarcinoma papilliferum. RESULTS: Mohs micrographic surgery with reconstruction of right auricle was performed subsequently. There are no signs of recurrence or metastasis 6 years after operation. CONCLUSION: Syringocystadenocarcinoma papilliferum can be successfully treated with Mohs micrographic surgery.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · 2013 · 33 citations · open access
Syringocystadenoma Papilliferum of the Scalp in an Adult Male – A Case Report
AbstractSyringocystadenoma papilliferum is a benign adnexal skin tumour of the apocrine or the eccrine type with characteristic histological features and varied and non-distinct clinical findings. It is relatively a rare neoplasm, which is called as a childhood tumour, since it usually appears at birth or during puberty. A case of syringocystadenoma papilliferum of the scalp in an adult male has been presented, which was clinically diagnosed at first as keratocanthoma of the scalp but was later histologically confirmed as syringocystadenoma papilliferum.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · 2014 · 12 citations · open access
Syringocystadenoma Papilliferum: An Unusual Presentation
AbstractSyringocystadenoma papilliferum is a benign hamartomatous adnexal tumour. Most of the patients present with solitary lesions in the head and neck region at birth or in early childhood. Multiple lesions are rarely seen and those which arise outside the head and neck region are even more uncommon. A case of syringocystadenoma papilliferum with multiple verrucous lesions and which was located in the right flank, an unusual site, has been presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
